Sermorelin + GHRP 6 Blend

Product Details: Sermorelin + GHRP-6 Blend

Sermorelin and GHRP-6 Blend are two somatotropic secretagogue agents studied together to potentially modulate hypothalamic-pituitary-somatotropic axis signaling. Sermorelin is a synthetic GHRH analog that induces anterior pituitary somatotroph function linked to GH secretion. GHRP-6 is a growth hormone secretagogue that also upregulates GH-associated pathways via GHS-R1a stimulation.

The combination of Sermorelin and GHRP-6 provides a synergistic effect in in vivo preclinical evaluations on animal-based experimental systems. In this blend, sermorelin is a synthetic growth hormone-releasing peptide that may affect the patterns linked with growth hormone release in laboratory specimens in the laboratory. When combined with GHRP-2, ghrelin receptors, the effects may be amplified in research models during controlled scientific studies.

By affecting GH release patterns, this blend may influence myofibrillar protein accretion and aerobic capacity indices in subjects during trial investigations.

This blend is offered as 5mg Sermorelin and 5mg GHRP-6, totaling 10 mg.

However, this product is intended for research purposes only and is not approved for human consumption or as an androgenic hormonal therapy. This blend should only be handled by licensed professionals for laboratory use.

How Does the Sermorelin + GHRP-6 Blend Work?

Sermorelin is a synthetic polypeptide made of a 29-residue amino acid sequence that acts as an endogenous GHRH analog. It modulates pituitary somatotroph activity to upregulate pulsatile secretion of endogenous human growth hormone. GHRP-6 is a growth hormone secretagogue, meaning it also potentiates growth hormone output. GHRP-6 is a synthetic agonist that activates the ghrelin receptor.

By blending sermorelin and GHRP-6, episodic somatotropin output is upregulated, leading to larger episodic somatotropin output compared to either compound alone. The increased pulsatile release of GH stimulated by this blend has the potential to upregulate the insulin-like growth factor type 1 pathway, positively modulating osteogenic activity and altering lean body mass distribution.

This may manifest in increased muscle protein synthesis, a reduction in lipid mass accumulation, and lowered BMI-derived anthropometric indices. The synergistic effects on GH release suggest potential outcomes such as adipose tissue reduction, increased lean tissue accrual, and altered serum biochemical metabolic indicators.

Through complementary mechanisms, sermorelin and GHRP-6 work together to potentiate GH output for outcomes on somatic composition, mass homeostasis modulation, and metabolic biomarkers.

Properties of Sermorelin + GHRP-6 Blend

Sermorelin

• CAS Number: 86168-78-7
• Molar Mass: 3357.93 g·mol−1
• Chemical Formula: C149H246N44O42S
• IUPAC Name: L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginine amide

GHRP-6

• CAS Number: 87616-84-0
• Molar Mass: 873.032 g·mol−1
• Chemical Formula: C46H56N12O6
• IUPAC Name: L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide

Please click here to see how purchases actually work on this site.